![](https://danskbiotek.dk/wp-content/uploads/2017/06/ymabs-300x139.jpg)
Y-mAbs Therapeutics Announces Pricing of Initial Public Offering 21 September 2018
NEW YORK, Sept. 20, 2018 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
NEW YORK, Sept. 20, 2018 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
Press Release: 17th September 2018 Today, BioPhero ApS has announced the closing of a seed investment... Read more
The FDA has granted Y-mAbs Breakthrough Therapy designation for naxitamab, in combination with GM-CSF,... Read more
Biotech and Money is an influential community of senior life science decision makers conducting impactful... Read more
Og denne mail er sikkert blot én i rækken af en endeløs mailstrøm, hvor du skal læse og tage stilling... Read more
Seventh Program to enter Clinical Development at Symphogen Symphogen’s antibody platform is now validated... Read more
DANISH BIO – DANSK BIOTEK afholdt i år ordinær generalforsamling den 9. maj hos Novo i forbindelse... Read more
Den 9. maj 2018 kl. 13.30 hos NOVO, Tuborg Havnevej 19, 2900 Hellerup Dagsorden c.f. vedtægterne: a. ... Read more
For et par uger siden præsenterede regeringen sin længe ventede Vækstplan for life science. I DANISH... Read more